Notice
- Important: This guidance is under active development by NHS England and content may be added or updated on a regular basis.
- This Implementation Guide is currently in Draft and SHOULD NOT be used for development or active implementation without express direction from the NHS England Genomics Unit.
Observation-GenomicTherapeuticImplication-Example
Example of an Observation representing a Therapeutic Implication derived from Genomic Testing.
Observation |
id : Observation-GenomicTherapeuticImplication-Example |
meta |
profile : http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication |
status : final |
category |
coding |
system : http://terminology.hl7.org/CodeSystem/observation-category |
code : laboratory |
category |
coding |
system : http://terminology.hl7.org/CodeSystem/v2-0074 |
code : GE |
code |
coding |
system : http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs |
code : therapeutic-implication |
subject |
reference : Patient/Patient-PheobeSmitham-Example |
effective : 2023-09-16 |
performer |
identifier |
system : https://fhir.nhs.uk/Id/ods-organization-code |
value : R0A |
derivedFrom |
reference : Observation/Oservation-GenomicsVariant-SLC52A2 |
component |
code |
coding |
system : http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs |
code : therapeutic-implication |
display : Therapeutic Implication |
value |
coding |
system : http://loinc.org |
code : LA9661-5 |
display : Presumed responsive |
component |
code |
coding |
system : http://loinc.org |
code : 51963-7 |
display : Medication assessed |
value |
coding |
system : http://snomed.info/sct |
code : 777436008 |
display : Riboflavin |
note |
text : High dose riboflavin supplementation has been reported to ameliorate the progression of this disorder (Foley et al 2014 PMID22740598) |
{ "resourceType": "Observation", "id": "Observation-GenomicTherapeuticImplication-Example", "meta": { "profile": [ "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication" ] }, "status": "final", "category": [ { "coding": [ { "system": "http://terminology.hl7.org/CodeSystem/observation-category", "code": "laboratory" } ] }, { "coding": [ { "system": "http://terminology.hl7.org/CodeSystem/v2-0074", "code": "GE" } ] } ], "code": { "coding": [ { "system": "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs", "code": "therapeutic-implication" } ] }, "subject": { "reference": "Patient/Patient-PheobeSmitham-Example" }, "effectiveDateTime": "2023-09-16", "performer": [ { "identifier": { "system": "https://fhir.nhs.uk/Id/ods-organization-code", "value": "R0A" } } ], "derivedFrom": [ { "reference": "Observation/Oservation-GenomicsVariant-SLC52A2" } ], "component": [ { "code": { "coding": [ { "system": "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs", "code": "therapeutic-implication", "display": "Therapeutic Implication" } ] }, "valueCodeableConcept": { "coding": [ { "system": "http://loinc.org", "code": "LA9661-5", "display": "Presumed responsive" } ] } }, { "code": { "coding": [ { "system": "http://loinc.org", "code": "51963-7", "display": "Medication assessed" } ] }, "valueCodeableConcept": { "coding": [ { "system": "http://snomed.info/sct", "code": "777436008", "display": "Riboflavin" } ] } } ], "note": [ { "text": "High dose riboflavin supplementation has been reported to ameliorate the progression of this disorder (Foley et al 2014 PMID22740598)" } ] }
<Observation xmlns="http://hl7.org/fhir"> <id value="Observation-GenomicTherapeuticImplication-Example" /> <meta> <profile value="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication" /> </meta> <status value="final" /> <category> <coding> <system value="http://terminology.hl7.org/CodeSystem/observation-category" /> <code value="laboratory" /> </coding> </category> <category> <coding> <system value="http://terminology.hl7.org/CodeSystem/v2-0074" /> <code value="GE" /> </coding> </category> <code> <coding> <system value="http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs" /> <code value="therapeutic-implication" /> </coding> </code> <subject> <reference value="Patient/Patient-PheobeSmitham-Example" /> </subject> <effectiveDateTime value="2023-09-16" /> <performer> <identifier> <system value="https://fhir.nhs.uk/Id/ods-organization-code" /> <value value="R0A" /> </identifier> </performer> <note> <text value="High dose riboflavin supplementation has been reported to ameliorate the progression of this disorder (Foley et al 2014 PMID22740598)" /> </note> <derivedFrom> <reference value="Observation/Oservation-GenomicsVariant-SLC52A2" /> </derivedFrom> <component> <code> <coding> <system value="http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs" /> <code value="therapeutic-implication" /> <display value="Therapeutic Implication" /> </coding> </code> <valueCodeableConcept> <coding> <system value="http://loinc.org" /> <code value="LA9661-5" /> <display value="Presumed responsive" /> </coding> </valueCodeableConcept> </component> <component> <code> <coding> <system value="http://loinc.org" /> <code value="51963-7" /> <display value="Medication assessed" /> </coding> </code> <valueCodeableConcept> <coding> <system value="http://snomed.info/sct" /> <code value="777436008" /> <display value="Riboflavin" /> </coding> </valueCodeableConcept> </component> </Observation>